Want to see HK:2898 full AI Analyst Report?
Sunho Biologics,Inc. (2898) AI Stock Analysis
Sunho Biologics,Inc.
(HKEX:2898)
Dominant weak financials with revenue collapse and cash burn heavily weigh down score; technical oversold signals and potentially undervalued price provide minor offset.
Sunho Biologics,Inc. (2898) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.00B
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -8.7
- Beta (1Y)
- 0.01
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 130
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Sunho Biologics,Inc. Business Overview & Revenue Model
Company Description
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby...
Sunho Biologics,Inc. Financial Statement Overview
Summary
Extremely weak income statement with 98% revenue decline and deep losses, poor cash flow with ongoing burn, and unstable balance sheet despite some equity improvement.
Income Statement
15Very NegativeBalance Sheet
38NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.00K | 38.00K | 17.53M | 1.73M | 3.22M |
| Gross Profit | -5.34M | 38.00K | 138.00K | 473.00K | 3.22M |
| EBITDA | -80.25M | -91.92M | -123.37M | -38.11M | -60.53M |
| Net Income | -82.09M | -79.97M | -132.70M | -51.99M | -70.63M |
Balance Sheet | |||||
| Total Assets | 557.88M | 560.74M | 290.45M | 70.86M | 84.95M |
| Cash, Cash Equivalents and Short-Term Investments | 441.40M | 457.28M | 210.07M | 1.82M | 10.66M |
| Total Debt | 68.24M | 41.20M | 9.07M | 11.03M | 160.86M |
| Total Liabilities | 76.62M | 48.80M | 394.56M | 72.36M | 216.50M |
| Stockholders Equity | 481.27M | 511.94M | -104.11M | -1.50M | -131.55M |
Cash Flow | |||||
| Free Cash Flow | -64.30M | -158.28M | -41.68M | -36.02M | -58.17M |
| Operating Cash Flow | -22.75M | -109.02M | -40.65M | -34.59M | -52.65M |
| Investing Cash Flow | -312.55M | -345.04M | -83.89M | -1.36M | -10.36M |
| Financing Cash Flow | 19.37M | 406.53M | 255.50M | 27.10M | 64.98M |
Sunho Biologics,Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2898, the sentiment is Negative. The current price of 6.39 is above the 20-day moving average (MA) of 6.39, above the 50-day MA of 6.39, and below the 200-day MA of 6.42, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 46.88 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2898.
Sunho Biologics,Inc. Peers Comparison
Overall Rating
HK:226981Outperform
HK:154871Outperform
HK:231569Neutral
HK:269664.6Neutral- HK:289842Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2269 | 81Outperform | HKD 183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% |
| HK:1548 | 71Outperform | HKD 79.58B | -14.95 | -16.23% | ― | 53.48% | -120.02% |
| HK:2315 | 69Neutral | HKD 17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:2898 | 42Neutral | HKD 970.43M | -8.74 | -39.21% | ― | ― | ― |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:2898 | Sunho Biologics,Inc. | 6.39 | -1.61 | -20.13% | |
| HK:1548 | Genscript Biotech Corporation | 35.02 | 17.98 | 105.52% | |
| HK:2269 | Wuxi Biologics (Cayman) | 44.48 | 8.86 | 24.87% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
Sunho Biologics,Inc. Corporate Events
Sunho Biologics Sets New Board and Committee Line-Up
Sunho Biologics, Inc., incorporated in the Cayman Islands and listed in Hong Kong under stock code 2898, operates in the biotechnology and life sciences sector. The company is focused on developing biological products, and its governance structure fe...
Sunho Biologics Director to Exit as Share Trading Suspension Persists
Sunho Biologics has announced that non-executive director Fan Rongkui will leave the board when his service contract expires on July 22, 2026. The company stated that Fan has no disagreements with the board based on information currently available, a...
Sunho Biologics Shareholders Approve Auditor Switch at Extraordinary Meeting
Sunho Biologics, Inc. shareholders convened an extraordinary general meeting on June 29, 2026, where they voted on changes to the company’s external auditors. All 156,666,800 issued shares were eligible to vote, and no shareholders were require...
Sunho Biologics outlines progress on investigation, controls ahead of trading resumption
Sunho Biologics has provided a quarterly update on its efforts to resume trading of its shares on the Hong Kong Stock Exchange following delays in publishing its 2025 annual results and a resulting suspension. The company has appointed CLA Advisory (...
Sunho Biologics Names Forensic Investigator as Trading Suspension Persists
Sunho Biologics, Inc. has appointed CLA Advisory (Hong Kong) Limited as an independent forensic investigator to conduct a probe into previously identified matters that led to delayed publication of its 2025 annual results. The investigator, selected...
Sunho Biologics Calls EGM to Approve Change of Auditor
Sunho Biologics, Inc. has called an extraordinary general meeting for June 29, 2026 in Nanjing to seek shareholder approval relating to changes in its external audit arrangements. The meeting will confirm and ratify the resignation of ZHONGHUI ANDA C...
Sunho Biologics Replaces Auditor Amid Delay in 2025 Results and Listing Risk
Sunho Biologics has announced the resignation of its auditor Zhonghui Anda, effective June 5, 2026, after the firm was unable to complete the audit work needed to finalize the company’s 2025 annual results. The delay has left the results outsta...
Sunho Biologics Sets Up Independent Probe as Trading Suspension Persists
Sunho Biologics has formed an Independent Investigation Committee, composed of three independent non-executive directors and chaired by Anthony Chan Heung Wing, to conduct a forensic investigation into matters linked to the company’s delayed 20...
Sunho Biologics Ordered to Meet Strict Conditions for Share Trading Resumption
Sunho Biologics has received formal resumption guidance from the Hong Kong Stock Exchange after trading in its shares was suspended due to delays in publishing its 2025 annual results and related governance concerns. The exchange has ordered an indep...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 30, 2026